3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
5
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
72
Lung Neoplasms
9
Adenocarcinoma of Lung
7
Brain Neoplasms
5
Non-squamous Non-small Cell Lung Cancer
4
NSCLC
4
Adenocarcinoma
4
Mesothelioma, Malignant
3
Colorectal Neoplasms
3
Nonsquamous Non-Small Cell Lung Cancer
2
Non-squamous Cell Non-Small Cell Lung Cancer
2
Neoplasms
2
Meningeal Carcinomatosis
2
Lymphoma
2
Glioma
2
Central Nervous System Neoplasms
2
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Untreated Advanced Non-Small Cell Lung Cancer
1
Unresectable Stage III NSCLC
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Stereotactic Radiotherapy; Evoximab (AK112); New Adjuvant Therapy for Non-small Cell Lung Cancer
1
Staging IV NSCLC
1
Squamous Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Respiratory Tract Neoplasms
1
Interventions
apatinib
2
Injections
2
Carboplatin
2
toripalimab
1
sintilimab
1
camrelizumab
1
Vinorelbine
1
Ultrasonography
1
TNFSF10 protein, human
1
Sodium Chloride
1
Pemetrexed
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Bevacizumab
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Thoracic Neoplasms
×
Pemetrexed
×
Clear all
NCT03402048
2020-11-04
EPIC
University of Turin, Italy
Phase 3
Unknown
567 enrolled